Tags

Type your tag names separated by a space and hit enter

Is it reasonable to add preoperative serum level of CEA and CA19-9 to staging for colorectal cancer?
J Surg Res. 2005 Apr; 124(2):169-74.JS

Abstract

BACKGROUND

Carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) are the most common tumor markers for colorectal cancer. The aim of this study was to evaluate the possibility of adding them into the current staging system by analyzing their prognostic significance.

MATERIALS AND METHODS

The study population was patients (n = 574, 67.1 +/- 11.3 years old, 397 males) who received potentially curative resection of colorectal adenocarcinoma (stage I-III) between January 1994 and August 2002, including preoperative measurements of CEA and CA19-9. Clinicopathological characteristics and associated follow-up data were retrospectively collected by reviewing available medical charts. CEA higher or equal to 5 ng/ml was defined as abnormal (CEA+). The CA19-9 level was set at 37 U/ml (CA19-9+). Patients were further divided into four groups (1, 2, 3, 4) according to the results of these two markers (CEA/CA19-9: -/-, -/+, +/-, and +/+). Survival was analyzed for AJCC staging, CEA (+) versus (-), CA19-9 (+) versus (-), and four groups.

RESULTS

CEA and CA19-9 survival curves were not significantly different. However, the combined use of the two markers revealed a significant survival benefit (P = 0.035) of group 1 ("-" for both markers) over 4 ("+" for both) in stage II.

CONCLUSIONS

Patients with an elevated level of both CEA and CA19-9 in stage II of colorectal cancer have a significantly poorer prognosis than those with normal levels of these markers. We recommend adding both CEA and CA19-9 to the current staging system.

Authors+Show Affiliations

Division of Colon and Rectal Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

15820244

Citation

Chen, Chien-Chih, et al. "Is It Reasonable to Add Preoperative Serum Level of CEA and CA19-9 to Staging for Colorectal Cancer?" The Journal of Surgical Research, vol. 124, no. 2, 2005, pp. 169-74.
Chen CC, Yang SH, Lin JK, et al. Is it reasonable to add preoperative serum level of CEA and CA19-9 to staging for colorectal cancer? J Surg Res. 2005;124(2):169-74.
Chen, C. C., Yang, S. H., Lin, J. K., Lin, T. C., Chen, W. S., Jiang, J. K., Wang, H. S., & Chang, S. C. (2005). Is it reasonable to add preoperative serum level of CEA and CA19-9 to staging for colorectal cancer? The Journal of Surgical Research, 124(2), 169-74.
Chen CC, et al. Is It Reasonable to Add Preoperative Serum Level of CEA and CA19-9 to Staging for Colorectal Cancer. J Surg Res. 2005;124(2):169-74. PubMed PMID: 15820244.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Is it reasonable to add preoperative serum level of CEA and CA19-9 to staging for colorectal cancer? AU - Chen,Chien-Chih, AU - Yang,Shung-Haur, AU - Lin,Jen-Kou, AU - Lin,Tzu-Chen, AU - Chen,Wei-Shone, AU - Jiang,Jeng-Kae, AU - Wang,Huann-Sheng, AU - Chang,Shih-Ching, PY - 2004/04/14/received PY - 2005/4/12/pubmed PY - 2005/5/25/medline PY - 2005/4/12/entrez SP - 169 EP - 74 JF - The Journal of surgical research JO - J. Surg. Res. VL - 124 IS - 2 N2 - BACKGROUND: Carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) are the most common tumor markers for colorectal cancer. The aim of this study was to evaluate the possibility of adding them into the current staging system by analyzing their prognostic significance. MATERIALS AND METHODS: The study population was patients (n = 574, 67.1 +/- 11.3 years old, 397 males) who received potentially curative resection of colorectal adenocarcinoma (stage I-III) between January 1994 and August 2002, including preoperative measurements of CEA and CA19-9. Clinicopathological characteristics and associated follow-up data were retrospectively collected by reviewing available medical charts. CEA higher or equal to 5 ng/ml was defined as abnormal (CEA+). The CA19-9 level was set at 37 U/ml (CA19-9+). Patients were further divided into four groups (1, 2, 3, 4) according to the results of these two markers (CEA/CA19-9: -/-, -/+, +/-, and +/+). Survival was analyzed for AJCC staging, CEA (+) versus (-), CA19-9 (+) versus (-), and four groups. RESULTS: CEA and CA19-9 survival curves were not significantly different. However, the combined use of the two markers revealed a significant survival benefit (P = 0.035) of group 1 ("-" for both markers) over 4 ("+" for both) in stage II. CONCLUSIONS: Patients with an elevated level of both CEA and CA19-9 in stage II of colorectal cancer have a significantly poorer prognosis than those with normal levels of these markers. We recommend adding both CEA and CA19-9 to the current staging system. SN - 0022-4804 UR - https://www.unboundmedicine.com/medline/citation/15820244/Is_it_reasonable_to_add_preoperative_serum_level_of_CEA_and_CA19_9_to_staging_for_colorectal_cancer L2 - https://linkinghub.elsevier.com/retrieve/pii/S0022-4804(04)00536-0 DB - PRIME DP - Unbound Medicine ER -